BioMarin Pharmaceutical Inc. (BMRN:NASDAQ) closed at $56.03 on November 6, 2026, down 0.16% on the day. The stock trades 21.1% below its 52-week high of $70.98 and 13.7% above its 52-week low of $49.26. Over the past year, it gained 8.9%. BioMarin Pharmaceutical Inc. is part of the Health Care sector (Major Pharmaceuticals).
In 252 trading sessions since November 6, 2025, BMRN closed higher on 117 days (46%). Its best day was December 19, 2025 (+17.71%) and its worst was January 13, 2026 (-4.35%). The stock moved 10% or more in a single session 1 time. It opened at least 5% above the previous day's high 1 time.
BioMarin Pharmaceutical Inc. develops and commercializes pharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and internationally. Its commercial products include Aldurazyme used for the treatment of patients with mucopolysaccharidosis I, a genetic disease; Kuvan, a proprietary synthetic oral form of 6R-BH4 used to treat patients with phenylketonuria (PKU), an inherited metabolic disease; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with mucopolysaccharidosis VI; and Vimizim, an enzyme replacement therapy for the treatment of MPS IV A, a lysosomal storage disorder. The company also conducts clinical trials on several investigational product candidates for the treatment of various diseases, including Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis, a form of Batten disease; pegvaliase, an enzyme substitution therapy for the treatment of PKU; vosoritide, a peptide therapeutic for the treatment of achondroplasia; BMN 270, an AAV VIII vector and Factor VIII gene therapy drug development candidate, for the treatment of hemophilia A; and BMN 250, a novel fusion of alpha-N-ac...
Find more stocks like BMRN with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.